Anixa Biosciences Inc (ANIX) Stock AnalysisANIXStock AnalysisAnixa Biosciences Inc

Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics program consists of the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (CAR-T) technology, initially focused on treating ovarian cancer, that is being developed of its subsidiary, Certainty Therapeutics, Inc. (Certainty). Its vaccine programs include the development of a vaccine against breast cancer, the development of a vaccine against ovarian cancer, and a vaccine discovery program utilizing the same mechanism of its breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. It is also developing a method to vaccinate women against breast cancer, focused on triple-negative breast cancer. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Anixa Biosciences Inc is a good buy right now due to its recent patent grants for a breast cancer vaccine, which enhance its competitive position and potential for future revenue. The current price is $3.48, significantly lower than the analyst price target of $10, indicating a potential upside of 187%. Additionally, the company has a strong current ratio of 12.18, suggesting good liquidity to support operations despite ongoing losses. The main risk is the negative earnings per share (EPS) of -0.07 reported last quarter, indicating continued financial challenges.

1 analysts cover ANIX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.00.